** Shares of gene therapy firm Bluebird Bio BLUE.O down 8.7% at $4.08 premarket
** BLUE says privately held UK company Ayrmid Ltd has not submitted binding proposal to acquire it and has not obtained necessary financing
** Co in March received non-binding offer from Ayrmid for up to $110.5 million
** BLUE adds it continues to be at significant risk of defaulting on its loan covenants
** Co's board reaffirms its recommendation in support of transaction with Carlyle CG.O and SK Capital, while recommending all stockholders tender into current agreement by May 2
** BLUE agreed to be taken private by Carlyle and SK Capital Partners at discount in February
** As of last close, stock has fallen 46.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。